
New abstracts show the oral PCSK9 inhibitor cut LDL-C by 57% to 63% across PREVENT risk groups, with reductions maintained in an extension study.
The American Journal of Managed Care
almost 28 years ago
Evaluation of Anemiaalmost 28 years ago
The Role of Clinical Practice Guidelines in Disease Managementalmost 28 years ago
Pharmacist Compensation for Ambulatory Patient Care Servicesalmost 28 years ago
Trends in Costs of Percutaneous Transluminal Coronary Angioplasty





